Omeros Corporation (OMER) announced a research collaboration alliance with the University of Cambridge, establishing the Omeros Center for Complement and Inflammation Research (OC3IR). The OC3IR is currently focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway. OMS721 is currently in three Phase 3 clinical programs-stem cell transplant-associated thrombotic microangiopathy, IgA nephropathy and atypical hemolytic uremic syndrome—and OMS906 is planned to enter the clinic in early 2020. Omeros holds proprietary positions around both MASP-2 and MASP-3. See their pipeline. They have an approved drug, OMIDRIA®which is marketed for the use during cataract surgery or intraocular lens (IQL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.
Based in Seattle, Omeros was founded in 1994. They have spent over $350 million in capital raised. They are currently operating with losses hovering around $100 million per year. With $55 million in cash they have a present market capitalization at $709 million and $14.40 per share.